Everything below concerns PT-141. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-16. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Boletus edulis fruit bodies contain diverse phytochemicals, including 500 mg of ergosterol per 100 g of dried mushroom, and ergothioneine. The fruit bodies contain numerous polyphenols, especially a high content of rosmarinic acid, and organic acids (such as oxalic, citric, malic, succinic and fumaric acids), and alkaloids.
=== Selected books === Mechanisms of Drug Resistance in Neoplastic Cells (1988) ISBN 9780127633626 Preclinical and Clinical Modulation of Anticancer Drugs (1993) ISBN 9780849372919 Basic Science of Cancer (2000) ISBN 9781468484397 Advances in Cancer Research (2014) ISBN 9780124071902
==== Cyclin E ==== As processes in cell cycle progression are the most fundamental processes for cellular growth and differentiation, and are the most common to be altered in human carcinomas, it is expected for cell cycle-regulatory proteins to be under tight regulation. The level of cyclins, as the name suggests, is high only at certain a time point during the cell cycle. This is achieved by continuous control of cyclins or CDKs levels through ubiquitylation and degradation. When cyclin E is partnered with CDK2 and gets phosphorylated, an SCF-associated F-box protein Fbw7 recognizes the complex and thus targets it for degradation. Mutations in Fbw7 have been found in more than 30% of human tumors, characterizing it as a tumor suppressor protein.
Maryanoff (born 1949), American organic/medicinal chemist Maud Menten (1879–1960), Canadian biochemist Helen Vaughn Michel (born 1932), American nuclear chemist Alexandra Navrotsky (born 1943), American geochemist Dorothy Virginia Nightingale (1902–2000), American organic chemist Yolanda Ortiz (chemist) (1924–2019), Argentine chemist, environmentalist Kathlyn Parker, American organic chemist Emma Parmee, British-born medicinal/organic chemist Marguerite Perey (1909–1975), French physicist, student of Marie Curie, discovered the element francium in 1939 Mary Engle Pennington (1872–1952), American food chemist Eva Philbin (1914–2005), Irish chemist Iphigenia Photaki (1921–1983), Greek organic chemist Darshan Ranganathan (1941–2001), Indian organic chemist Mildred Rebstock (1919–2011), American Pharmaceutical chemist Sibyl Martha Rock (1909–1981), American pioneer in mass spectrometry and computing Elizabeth Rona (1890–1981), Hungarian (naturalized American) nuclear chemist and polonium expert Mary Swartz Rose (1874–1941), Nutrition chemist Melanie Sanford (born 1975), American organic chemist Maxine L. Savitz, American Chemist Patsy Sherman (1930–2008), American chemist, co-inventor of Scotchgard Odette L.
The sans-culottes ... campaigned for a more democratic constitution, price controls, harsh laws against political enemies, and economic legislation to assist the needy. They expressed their demands through petitions of the sections presented to the assemblies (the Legislative, and Convention) by the delegates. The sans-culottes had a third way of applying pressure to achieve their demands: the police and the courts received thousands of denunciations of traitors and supposed conspirators. The height of their influence spanned roughly from the original overthrow of the monarchy in 1792 to the Thermidorian Reaction in 1794. Throughout the revolution, the sans-culottes provided the principal support behind the more radical and anti-bourgeoisie factions of the Paris Commune, such as the Enragés and the Hébertists, and were led by populist revolutionaries such as Jacques Roux and Jacques Hébert.
Sources: en.wikipedia.org
This requires advanced knowledge of biology. Murex-based dyeing must take place close to the site from which the snails originate, because the freshness of the material has a significant effect on the results, the colours yielded based on the long process of biochemical, enzymatic and photochemical reactions, and requires reduction and oxidation processes that probably took several days.
=== Cardiovascular disease === The primary health risk identified for trans fat consumption is an elevated risk of coronary artery disease (CAD). A 1994 study estimated that over 30,000 cardiac deaths per year in the United States are attributable to the consumption of trans fats. By 2006 upper estimates of 100,000 deaths were suggested. Major evidence for the effect of trans fat on CAD comes from the Nurses' Health Study – a cohort study that has been following 120,000 female nurses since its inception in 1976. In this study, Hu and colleagues analyzed data from 900 coronary events from the study's population during 14 years of followup. He determined that a nurse's CAD risk roughly doubled (relative risk of 1.93, CI: 1.43 to 2.61) for each 2% increase in trans fat calories consumed (instead of carbohydrate calories). By contrast, for each 5% increase in saturated fat calories (instead of carbohydrate calories) there was a 17% increase in risk (relative risk of 1.17, CI: 0.97 to 1.41). "The replacement of saturated fat or trans unsaturated fat by cis (unhydrogenated) unsaturated fats was associated with larger reductions in risk than an isocaloric replacement by carbohydrates." Hu also reports on the benefits of reducing trans fat consumption. Replacing 2% of food energy from trans fat with non-trans unsaturated fats more than halves the risk of CAD (53%). By comparison, replacing a larger 5% of food energy from saturated fat with non-trans unsaturated fats reduces the risk of CAD by 43%.
=== Acidity === Carboxylic acids are Brønsted–Lowry acids because they are proton (H+) donors. They are the most common type of organic acid. Carboxylic acids are typically weak acids, meaning that they only partially dissociate into [H3O]+ cations and R−CO−2 anions in neutral aqueous solution. For example, at room temperature, in a 1-molar solution of acetic acid, only 0.001% of the acid are dissociated (i.e. 10−5 moles out of 1 mol). Electron-withdrawing substituents such as trifluoromethyl (−CF3) give stronger acids (the pKa of acetic acid is 4.76 whereas trifluoroacetic acid, with a trifluoromethyl substituent, has a pKa of 0.23). Electron-donating substituents give weaker acids (the pKa of formic acid is 3.75 whereas acetic acid, with a methyl substituent, has a pKa of 4.76)
The United Kingdom committed the largest contingent of any European state that participated in the war's combat operations. Operation Granby was the code name for the operations in the Persian Gulf. British Army regiments (mainly with the 1st Armoured Division), Royal Air Force, Naval Air Squadrons and Royal Navy vessels were mobilized in the Persian Gulf. Both Royal Air Force and Naval Air Squadrons, using various aircraft, operated from airbases in Saudi Arabia and Naval Air Squadrons from vessels in the Persian Gulf. The United Kingdom played a major role in the Battle of Norfolk, where its forces destroyed over 200 Iraqi tanks and a large quantity of other vehicles. After 48 hours of combat the British 1st Armoured Division destroyed or isolated four Iraqi infantry divisions (the 26th, 48th, 31st, and 25th), and overran the Iraqi 52nd Armored Division in several sharp engagements. Chief Royal Navy vessels deployed to the Persian Gulf included Broadsword-class frigates, and Sheffield-class destroyers. Other R.N. and RFA ships were also deployed. The light aircraft carrier HMS Ark Royal was deployed to the Mediterranean Sea. Several SAS squadrons were deployed. A British Challenger 1 achieved the longest range confirmed tank kill of the war, destroying an Iraqi tank with an armour-piercing fin-stabilized discarding-sabot (APFSDS) round fired over 4,700 metres (2.9 mi)—the longest tank-on-tank kill shot ever recorded.
=== NSAIDs === Unless otherwise contraindicated, all people with AS are recommended to take non-steroidal anti-inflammatory drugs (NSAIDs). The dose, frequency, and specific drug may depend on the individual and the symptoms they experience. NSAIDs, such as ibuprofen and naproxen, are used to alleviate pain, reduce inflammation, and improve joint stiffness associated with AS. These medications work by inhibiting the activity of cyclooxygenase (COX) enzymes, which are involved in the production of inflammatory prostaglandins. By reducing the levels of prostaglandins, NSAIDs help mitigate the inflammatory response and relieve symptoms in individuals with ankylosing spondylitis.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.